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Poster Session I 69Introduction: Autologous stem cell transplantation is accepted
therapy for most younger patients with multiple myeloma (MM)
following steroid-based induction therapy. Use of dose-intense sal-
vage chemotherapy, such as D-PACE, in steroid-refractory MM
may adversely affect stem cell harvesting. Bortezomib (Bor), an
agent with a novel mechanism of action against MM, may be syner-
gistic to alkylating agents, and does not affect stem cell yield in pre-
treated patients.We piloted the addition of Bor to high-dose cyclo-
phosphamide (Cy) during stem cell harvesting in a series of patients
refractory to D-PACE salvage therapy. Patients and Methods: 17
MM patients refractory to 3 or more cycles of steroid-based induc-
tion therapy received 2 cycles of D-PACE in prior to proceeding to
autologous stem cell harvesting. 7 patients achieved adequate cytor-
eduction and proceeded to high-dose Cy (3 g/m2) and G-CSF plus
SCF stimulation for mobilization. In 10 patients not achieving ad-
equate disease cytoreduction, Bor was added to the mobilization
regimen prior to high-dose Cy. Response assessment included
time to stem cell harvest, number of CD34 cells harvested, disease
response, and effect on hematologic parameters. Results: Toxic-
ities arising from D-PACE were similar in both groups. The com-
bination Bor/Cy mobilization regimen did not lead to increased
symptomatic toxicity. Grade 3/4 thrombocytopenia occurred in 6/
10 patients receiving combination therapy. No significant bleeding,
peripheral neuropathy, or skin rash occured. The average CD341
stem cell harvest in both groups was .5.0  106/kg., and favored
the combination group. Time to adequate stem cell harvest was sim-
ilar between the groups. The harvested product from the Bor/Cy
group consistently demonstrated \2% cells bearing plasma cell
markers by flow cytometry. 1 patient in each group failed to mobi-
lize sufficient stem cells for an adequate harvest. Bone marrow
plasma cell content following Bor/Cy harvesting decreased in all as-
sessed patients. Time to engraftment was similar in both groups.
Data on post-transplant disease control and survival will be pre-
sented. Presence of unfavorable cytogenetics or ISS stage at diagno-
sis did not appear to affect response to Bor/Cy therapy.
Conclusion: The addition of Bor to high-dose Cy during stem
cell mobilization does not increase toxicity or decrease stem cell
harvest yield or quality, and achieves adequate disease reduction
in patients refractory to salvage chemotherapy.187
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Background: Non-myeloablative conditionings combined
fludarabin and cyclophosphamide (FLU-CY) with or without
antithymocyte globulin (ATG) and low-dose total body irradiation
(LD-TBI) may be used in the patients allografted for malignant
lymphomas. Significant immunosuppressionwithout severe toxicity
allows to engraft donor cells responsible for desirable graft versus
lymphoma (GvL) reaction. Patients and Methods: 20 patients
with the age median of 49 (range 27–58) years were allografted
for relapsed and/or refractory malignant lymphoproliferative dis-
eases: 5 B chronic lymphocytic leukemia (B-CLL), 4Hodgkin’s
lymphoma (HL), 8 B and 3 T non-Hodgkin’s lymphoma
(NHL). 9 patients (45%) were conditioned with FLU-CY. ATG
only was added to FLU-CY in 6 cases (30%), ATG and LD-TBI
in 5 ones (25%). 9 patients (45%) received the graft from sibling,
6 (30%)matched unrelated and 5 ones (25%)mismatched unrelated
donor. Peripheral blood and bone marrow were the source of stem
cells in 17 (85%) and 3 cases (15%), respectively. The median of
transfused CD341 cells was 5.03 (range 2.5–8.8) 106/kg of recip-
ient body weight. Graft versus host disease (GvHD) prophylaxis
with cyclosporine A (CSP-A) only was administered to 10 recipients
(50%). Mycophenolate mofetil (MMF) and methotrexate (MTX)
were added to CSP-A in 9 (45%) and 1 cases (5%), respectively.
The median of posttransplant follow-up was 1.6 (range 0.3–5.7)
years. Results: All recipients engrafted and non-hematologicaltoxicity did not exceed the grade I. 10 ones (50%) developed acute
GvHD. Chronic GvHD was observed in 10 of 18 assessable cases
(55.6%). All patients (100%) achieved complete remission (CR) of
lymphoma. 4 ones (20%) relapsed and 2 of them (10%) died of tu-
mor progression. 7 recipients (35%) died of posttransplant compli-
cations. Estimated 5-year event-free (EFS) and overall survival (OS)
were 27% and 29%, respectively. Conclusion: The results con-
firmed a possibility to cure recurrent/refractory lymphoma by
GvL reaction without the previous significant tumor burden reduc-
tion.Nevertheless, GvHDand associated complications still remain
the main cause of posttransplant morbidity and mortality.
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VAGE THERAPY FOR HODGKIN’S LYMPHOMA
Shafer, J.A.1,3, Heslop, H.E.1,2,3, Carrum, G.1,2, Kamble, R.1,2,
Myers, G.D.1,3, Leung, K.S.1,3, Bollard, C.M.1,2,3, Krance, R.A.1,2,3
1Baylor College ofMedicine; 2Baylor College ofMedicine; 3Baylor College
of Medicine, Houston, TX.
Survival Rates for patients diagnosed with Hodgkin’s lymphoma
(HL) approaches 90% irrespective of stage at initial diagnosis. But
for patients with primary refractory or relapsed disease the out-
comes are less favorable. High dose chemotherapy with stem cell
rescue has been shown to be the preferred salvage approach, with
overall survival rates ranging from 30–65%, compared to conven-
tional chemotherapy. Risk factors for poor outcomes include early
relapse and primary refractory disease and it is suggested that these
groupsmay benefit from allogenic transplant.However, the outlook
for patients with chemo-resistant disease is poor and it is unclear if
these patients receive any benefit from stem cell transplant. Here we
evaluate outcomes of patients who have received stem cell trans-
plant at our institution for relapsed or refractory Hodgkin’s disease.
A retrospective review of 42 patients who received their initial trans-
plant for Hodgkin’s disease between October of 1997 and June of
2007 at the Center for Cell and Gene Therapy in Houston, Texas
was performed. Indications for transplant included refractory dis-
ease at primary diagnosis or relapsed disease. 30 patients received
high dose chemotherapy with autologous stem cell rescue and 12
patients received an allogeneic HSCT. Indications for allogeneic
HSCT included chemorefractory disease and/or bone marrow in-
volvement of HL. The median age of the patients was 23.5 (range
12–60 years). Median time of follow up was 3 years (range 3 months
to 9 years). 5 year overall survival (OS) was 66% and progression
free survival (PFS) was 56%. Of the 7 patients transplanted (2
auto and 5 allo) with chemotherapy resistant disease only one pa-
tient survives (\1 year follow-up). The remaining 6 died within 3
years of SCT primarily due to disease progression. When these
highest risk patients with chemotherapy resistant disease are ex-
cluded in the analysis the OS and PFS after SCT is 76% and 66%
respectively. Our data supports the dismal results of patients with
chemo resistant disease, whereas patients with chemo-sensitive dis-
ease have a good chance of cure with HSCT.189
NON-MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION
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Allogeneic stem cell transplantation (SCT) can induce long term
remissions and some cures in multiple myeloma (MM). High treat-
ment related mortality (TRM) associated with such treatment mo-
dality has been the reason behind exploring non-myeloblative
conditioning regimens (NMA) in these patients. As part of a pro-
spective study evaluating NMA for hematologic malignancies in
our institution, 12 MM patients were enrolled between 2000–
2006. All patients were transplanted as either part of initial
